CLOs on the Move

Galderma Laboratories, L.P.

www.galderma.com

 
Galderma Laboratories, L.P. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Fort Worth, TX. To find more information about Galderma Laboratories, L.P., please visit www.galderma.com
  • Number of Employees: 25-100
  • Annual Revenue: > $1 Billion
  • www.galderma.com
  • 14501 North Fwy
    Fort Worth, TX USA 76177-3304
  • Phone: 817.961.5000

Executives

Name Title Contact Details
Devon Sharp
Associate General Counsel Profile
Grant Riedesel
Head of Legal, Corporate Development Profile
Tim Stow
Global Head of Ethics and Compliance Profile
Sean Griffin
Vice President of Regulatory Affairs Profile

Similar Companies

Computer and Allied Technology Solutions

Computer and Allied Technology Solutions is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Community Health Corporation

Community Health Corporation is a Plano, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alfie

Alfie uses precision tests to determine the right combination of prescription medication and 1:1 health coaching to optimize your weight loss.

HyHealth

HyHealth is a Toledo, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alnylam

Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.